Quince Therapeutics stock prepares for LAM-001 KOL event as shares trade below recent highs
Published on 09/18/2026 at 10:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Quince Therapeutics stock (ISIN US74833Q1004) traded at around USD 28.59 on Nasdaq as of September 17, 2026, leaving the clinical stage biotech below its recent intraday range between roughly USD 27 and USD 29 while investors focus on its respiratory pipeline.
Virtual KOL event spotlights LAM-001 program
According to Business Insider, Quince Therapeutics, Inc. (Nasdaq: QNCX) announced on September 17, 2026, that it will host a virtual key opinion leader event on September 28, 2026, from 12:30 p.m. to 2:00 p.m. Eastern Time to discuss the current treatment landscape for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and bronchiolitis obliterans syndrome (BOS) as well as the companys investigational therapy LAM-001.
The company described itself in the same announcement as a clinical stage biopharmaceutical company developing disease modifying therapies for serious, underserved diseases, underscoring that LAM-001 is a central asset in its pipeline targeting PH-ILD and BOS, two indications with limited treatment options.StockTitan
Stock trades in high-20 dollar range ahead of event
Per Nasdaq price data relayed by a Yahoo Finance overview on September 17, 2026, Quince Therapeutics stock changed hands at USD 28.59 in intraday trading, with the quote captured at 2:58:48 p.m. Eastern Time on the Nasdaq Global Select Market.Yahoo Finance
In a separate watchlist snapshot that included Quince Therapeutics, the stock was shown at USD 27.01 with a daily move of minus 0.59 percent as of a recent session in mid September 2026, highlighting that the shares have been oscillating around the high 20 dollar level over several trading days.Yahoo Finance
Next catalyst and investor focus
The September 28, 2026, KOL event gives Quince Therapeutics a timed platform to position LAM-001 within the evolving treatment standards for PH-ILD and BOS, and for investors the discussion could provide new clinical or strategic details that help gauge the potential market opportunity for this asset.StockTitan
Quince Therapeutics stock and valuation snapshot
With Quince Therapeutics stock most recently quoted around USD 28.59 on Nasdaq on September 17, 2026, the shares sit in the high 20 dollar band ahead of the late September KOL event, giving investors a clear near term date to watch for potential news flow.
Quince Therapeutics stock at a glance
- Company: Quince Therapeutics, Inc.
- ISIN: US74833Q1004
- Ticker: QNCX
- Trading venue: Nasdaq
